|
|
| | Gefitinib InterMediate B Basic information |
| Product Name: | Gefitinib InterMediate B | | Synonyms: | N-(3-chloro-4-fluorophenyl)-6-(3-chloropropoxy)-7-Methoxyquinazolin-4-aMine;Gefitinib InterMediate B;6-(3-chloropropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-ylamine;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-chloropropoxy)-7-methoxy-;Gefitinib InterMediate B ISO 9001：2015 REACH;N-(3-Chloro-4-fluorophenyl)-6-(3-chloropropoxy)-7-methoxy-4-quinazolinamine | | CAS: | 912556-91-3 | | MF: | C18H16Cl2FN3O2 | | MW: | 396.24 | | EINECS: | | | Product Categories: | | | Mol File: | 912556-91-3.mol |  |
| | Gefitinib InterMediate B Chemical Properties |
| Melting point | 234-236 °C | | Boiling point | 523.3±50.0 °C(Predicted) | | density | 1.392±0.06 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | pka | 5.40±0.30(Predicted) | | Appearance | White to off-white Solid |
| | Gefitinib InterMediate B Usage And Synthesis |
| Uses | 4-Chloro-6-(3-chloropropoxy)-7-methoxyquinazoline is an analogue of Gefitinib, an inhibitor of EGFR with anti-tumor activity. | | Synthesis | A mixture of 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (20.00 g), K2CO3 (10.37 g), KI (1.04 g), 1-bromo-3-chloropropane (7.50 mL), and DMF (150 mL) was stirred and reacted for 6 hours at 40 °C. After completion of the reaction, the reaction mixture was poured into water and the solid was collected by filtration. The filtrate was purified by silica gel column chromatography (eluent: ethyl acetate) to afford the target compound, N-(3-chloro-4-fluorophenyl)-6-(3-chloropropoxy)-7-methoxyquinazolin-4-amine, as a light yellow liquid (22.05 g, 89.00% yield). The structure of the compound was confirmed by the following spectral data: mass spectrum (ESI, positive ion mode) m/z: 396.1 ([M+H]+); 1H NMR (400 MHz, CDCl3) δ: 2.01 (m, 2H), 3.68 (t, J=4.2 Hz, 2H), 4.00 (s, 3H), 4.10 (t, J=4.2 Hz, 2H). 6.80 (s, 1H), 7.16 (s, 1H), 7.26 (s, 1H), 7.30 (s, 1H), 7.47 (s, 1H), 8.64 (s, 1H) ppm. | | References | [1] Patent: WO2013/71697, 2013, A1. Location in patent: Paragraph 00197
[2] Patent: US2014/228361, 2014, A1. Location in patent: Paragraph 0277-0278
[3] Patent: US2014/206664, 2014, A1. Location in patent: Paragraph 0225; 0229
[4] Patent: EP2796451, 2014, A1. Location in patent: Paragraph 0082 |
| | Gefitinib InterMediate B Preparation Products And Raw materials |
|